Skip to main content
Premium Trial:

Request an Annual Quote

Lynx s Revenues Fall, Loss Widens in Q4

NEW YORK, April 1 (GenomeWeb News) - Lynx Therapeutics yesterday reported falling revenues and increased losses for the last quarter of 2003.

 

Revenues for the quarter fell to $2 million, from $4.7 million for the same quarter in 2002. Lynx attributed this decrease primarily to lower fees for its technology and service, and fewer collaborative research projects.

 

R&D costs decreased to $2.4 million, down from $4.2 million during the year-ago period.

 

Lynx's net loss amounted to $3.5 million, or $.65 per share, up from $3 million, or $.69 per share, during the fourth quarter of 2002.

 

As of Dec. 31, Lynx had cash and cash equivalents of $5.6 million, including $0.7 million in restricted cash.

 

Click here for the full earnings report.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more